Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users
Recruitment status was Recruiting
The purpose of this study is to compare how safe, tolerable, and effective a novel drug, raltegravir, is to a commonly used combination, atazanavir/ritonavir, as initial treatment in HIV/Hepatitis C co-infected injecting drug users on a methadone program.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone|
- Incidence of grade 3-4 liver function test (LFT) elevations [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
- Incidence of grade 3-4 liver function test (LFT) elevations [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
- Incidence of grade 3-4 liver function test (LFT) elevations [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
- Incidence of grade 3-4 liver function test (LFT) elevations [ Time Frame: 36 weeks ] [ Designated as safety issue: Yes ]
- Incidence of grade 3-4 liver function test (LFT) elevations [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
- Incidence of grade 3-4 liver function test (LFT) elevations [ Time Frame: 60 weeks ] [ Designated as safety issue: Yes ]
- Incidence of grade 3-4 liver function test (LFT) elevations [ Time Frame: 72 weeks ] [ Designated as safety issue: Yes ]
- Incidence of grade 3-4 liver function test (LFT) elevations [ Time Frame: 84 weeks ] [ Designated as safety issue: Yes ]
- Incidence of grade 3-4 liver function test (LFT) elevations [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
- Viral suppression [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]Viral suppression is defined as HIV-1 RNA less than 50 copies per mL
- Viral suppression [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]Viral suppression is defined as HIV- RNA less than 50 copies per mL.
- Immunologic response [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]Recovery of CD4 count
- Overall safety in patients with mild to moderate hepatic impairment [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
- Outpatient retention rates [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
- QTc interval changes [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]Effects of pharmacological intervention on corrected QT interval on electrocardiogram
- Immunologic response [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
- Immunologic response [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||August 2010|
|Estimated Study Completion Date:||December 2012|
|Estimated Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|
Raltegravir in combination with Tenofovir/Emtricitabine
400mg orally twice daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.
Other Name: Isentress™
Active Comparator: Atazanavir/Ritonavir
Atazanavir 300mg orally once daily with Ritonavir 100mg orally once daily; together with combination of Tenofovir/Emtricitabine
Atazanavir 300mg orally once daily boosted with Ritonavir orally 100mg once daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.
Other Name: Reyataz™ (Atazanavir), Norvir™ (Ritonavir)
Hide Detailed Description
Raltegravir is an HIV-1 integrase inhibitor that is currently licensed for use in treatment-experienced HIV-1 patients and recently approved for use in treatment-naïve patients. Recent data has shown that the virologic response in patients on raltegravir with no history of antiretroviral treatment (ART) was equal to efavirenz-based therapy at 96-weeks (combined with tenofovir/lamivudine). Moreover, raltegravir demonstrated greater immunologic effect, had fewer adverse side effects and had a neutral effect on lipid levels. Further support for first-line use comes from recent 48-week data of a subgroup analyses of the STARTMRK Phase III study comparing raltegravir to efavirenz-based therapy (with tenofovir/emtricitabine) in treatment-naïve patients that showed non-inferior virologic and immunologic efficacy with raltegravir. There were significantly fewer overall and drug-related clinical adverse events in the raltegravir group and a similar safety profile in patients with hepatitis B and/or C co-infection. These findings suggest that use of raltegravir as a component of initial therapy might be beneficial in patients with significant co-morbidities such as hepatitis C and in situations where there is concern of interactions between antiretrovirals and other drugs.
Injecting drug users (IDUs) represent a patient group where there are formidable challenges in HIV treatment. Difficulties in management arise not only from substance abuse but also because of high rates of social instability and psychiatric co-morbidities. Furthermore, many in this patient group have hepatitis C co-infection. These confounding factors negatively impact adherence to, and ultimately the efficacy of treatment and can affect physician perception when prescribing antiretrovirals. Concurrent methadone therapy further complicates HIV treatment because of its potential side effects and interactions with antiretrovirals. However, methadone maintenance therapy also represents an important opportunity to engage patients in consistent medical care and has been shown to improve adherence to antiretroviral treatment and thus viral suppression.
The incidence of co-infection with HIV and hepatitis C virus (HCV) in IDUs is high. An estimated 50-90% of IDUs in the U.S. are co-infected with HIV/Hepatitis C according to the Center for Disease Control and Prevention. HIV co-infection aggravates the natural course of HCV infection. In a meta-analysis of the effect of HIV on the progression of HCV liver disease compared to mono-infection with HCV, the relative risk of end-stage liver disease (ESLD) and cirrhosis with HIV co-infection was found to be 6.14 and 2.07, respectively. Difficulties arise in the treatment of HIV with respect to HCV liver disease. Drug hepatotoxicity is a major concern in the selection of an appropriate antiretroviral regimen. Optimising therapy in this patient group necessitates a balance between retroviral suppression and minimising hepatic side effects.
Raltegravir is predominantly metabolised by hepatic glucuronidation via the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) isozyme. A small component is renally excreted (~9%). In three double-blind, randomised studies of pharmacokinetics, safety and tolerability, raltegravir was found to be rapidly absorbed with a terminal half-life of 7-12 hours. It exhibited potent in vitro inhibition with a 95% inhibitory concentration (IC95) = 33nM in 50% human serum. Pharmacokinetic analyses of various dosing regimens supported the use of twice daily dosing of multiple doses of 100mg and greater. Results from a study investigating once daily dosing are pending.
Hepatic impairment is less likely to affect UGT1A1 metabolism in comparison to other liver metabolic pathways. A recent study evaluated the effect of liver impairment on raltegravir pharmacokinetics in 20 HIV-negative patients (ten patients with moderate hepatic insufficiency and ten healthy, matched controls). The geometric mean ratios (GMR: mean value for the group with moderate hepatic insufficiency/mean value for the healthy controls) and 90% confidence intervals (CIs) for the area under the concentration-time curve from time zero to infinity (AUC0- ∞ ), the maximum concentration of drug in plasma (Cmax), and the concentration at 12 h (C12) were 0.86 (90% CI, 0.41, 1.77), 0.63 (90% CI, 0.23, 1.70), and 1.26 (90% CI, 0.65, 2.43), respectively. The study authors determined that liver impairment produced no clinically significant effects on raltegravir pharmacokinetics and therefore no dose adjustments are needed for mild to moderate hepatic insufficiency.
Protease inhibitors, such as atazanavir, are extensively metabolised via hepatic cytochrome P450 (CYP) 3A isozymes. In patients with hepatic insufficiency, dose adjustments of PIs or consideration of alternative therapies may be necessary. Atazanavir is also a potent inhibitor of CYP3A and therefore has a potential to cause drug interactions .
Concerns regarding adverse cardiac effects of antiretroviral therapy have recently emerged. Protease inhibitors have been associated with an increased risk of myocardial infarction that is partially due to dyslipidaemia. Ritonavir-boosted atazanavir is commonly used as part of combination treatment in IDUs because of its modest effect on lipid levels and also due to the simplicity of once daily dosing. However, it has other associated risk factors and intolerability due to hyperbilirubinaemia is also an issue.
There is also growing concern with reports of long QT syndrome and torsade de pointes in IDUs. This patient group have several risk factors that increase their susceptibility. Methadone is well recognised to cause long QT syndrome and torsades de pointes through inhibition of a cardiac potassium channel, the major component of which is encoded by the human ether-a-go-go gene (HERG). Multiple HERG polymorphisms have been identified that are clinically silent but may confer vulnerability to arrhythmia by a triggering event. Protease inhibitors also have the potential to cause QT prolongation. This may be mediated by direct effects on HERG channels or by potentiating the effects of other drugs through inhibition of CYP3A, or both. Concurrent use of protease inhibitors and methadone might pose an additive risk of QT prolongation and a few cases have been reported recently. Additionally, co-infection with hepatitis C is also recognised to prolong the QT interval.
Raltegravir has been shown to have no effect on the QT interval in a single, supratherapeutic dose in humans and in multiple doses in an animal model. It also exhibits negligible inhibition of HERG current in vitro and has been found to have little to no effect on cytochrome P450 enzymes.
In summary, efficacious virologic and immunologic response, safe use in hepatic impairment, non-inhibition of CYP enzymes, lack of QT effect, and favourable lipid and side effect profile indicate that raltegravir could be a preferred option for first-line treatment in this patient group.
This study will be carried out as a Phase 4, Multi-Centre Open Label, Investigator Led, Randomised Pilot Study to compare the efficacy, safety and tolerability of raltegravir (Isentress™) with protease inhibitor-based therapy atazanavir/ritonavir (Reyataz™/Norvir™) in treatment naïve, HIV/Hepatitis C co-infected injecting drug users receiving methadone. Patients who are attending a drug treatment clinic, who are on methadone maintenance therapy, who fulfill standard criteria to receive antiretroviral therapy (ART) and who meet all other study specific eligibility criteria will be invited to participate in the study.
Eligible patients, who are willing to participate in the study and who agree to comply with all study treatments and procedures, will be randomized to treatment with either:
- Raltegravir 400mg PO twice daily; or
- Atazanavir/ritonavir 300mg/100mg PO once daily over a 96 week treatment period.
As per the recommended guidelines, both treatment regimes will be combined with a nucleoside reverse-transcriptase inhibitor (NRTI) backbone of tenofovir and emtricitabine, but can be changed due to toxicities as per the discretion of the investigator or other medically qualified designee.
The total study duration for subjects completing the entire study will be approximately 100 weeks. During this time subjects will attend the clinic for 11 study visits at Baseline, Weeks 4, 12, 24, 36, 48, 60, 72, 84 and 96 and an End of Study Visit, 4 weeks post completion of treatment.
Subjects' participation in this study will end following the End of Study Visit (or early withdrawal visit if applicable). Once subjects have completed their participation in this study they will be treated as per routine standard care for this patient population.
Written informed consent will be obtained prior to any study procedures being conducted. Patients will have an initial baseline assessment prior to treatment initiation. This will include a medical history, physical examination and electrocardiogram. Baseline laboratory tests will include a resistance profile, CD4 count, viral load, hepatitis C status, full blood count, liver blood tests and renal profile.
Patients will be re-assessed at 4, 12, 24, 36, 48, 60, 72, 84 and 96 weeks post initiation for treatment efficacy, safety, tolerability and compliance. Follow-up blood tests will be drawn to assess virological and immunological response to treatment as well as routine blood tests to detect hepatitis C status, liver/renal toxicities and haematological abnormalities. ECG evaluation for QT abnormalities will be performed at baseline and at weeks 4, 12, 48 and 96. A follow up safety visit will be conducted 4 weeks post completion of therapy. Monitoring for adverse events will take place throughout the study period and continuity of care, as per standard medical care for this patient population, maintained after the patients have completed the study at the respective sites.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01105611
|Contact: Colm Bergin, MD, FRCPIfirstname.lastname@example.org|
|Contact: James Woo, MB, MRCPIemail@example.com|
|Department of Genitourinary Medicine and Infectious Diseases, St. James's Hospital||Recruiting|
|Contact: Colm Bergin, MD, FRCPI +35314162507 firstname.lastname@example.org|
|Contact: James Woo, MB, MRCPI +353868108086 email@example.com|
|Principal Investigator: Colm Bergin, MD, FRCPI|
|Sub-Investigator: James Woo, MB, MRCPI|
|Mater Misericordiae University Hospital||Not yet recruiting|
|Contact: Patrick Mallon, MB FRCPI PhD +35317166311 Paddy.Mallon@ucd.ie|
|Principal Investigator: Patrick Mallon, MB FRCPI PhD|
|Principal Investigator:||Colm Bergin, MD, FRCPI||Department of Genitourinary Medicine and Infectious Diseases, St. James's Hospital, Dublin, Ireland|